tirzepatide by mouth Oral Drops: Safety, Effectiveness, and What to Know Why Does Tirzepatide Cause Nausea

Retatrutide is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously, with Phase 2 trials using once-weekly subcutaneous doses of 1 mg to 12 mg

Here are the two criteria that the FDA uses to determine who is a candidate for GLP-1 medications

Should clinicians monitor gastric symptoms during long-term therapy

In clinical studies, people lost up to 20% of their body weight in just 72 weeks, results once thought possible only with bariatric surgery

Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal

What is the FDA-approved use of O zempic